Background and Purpose: While partial nephrectomy remains the gold standard for the management of most small renal masses, increasing experience with renal cryoablation has suggested a viable alternative with a favorable morbidity profile and good efficacy. We report intermediate-term oncologic outcomes from a singlecenter experience with laparoscopic and percutaneous renal cryoablation. Patients and Methods: We performed a retrospective review of our laparoscopic renal cryoablation (LRC) and percutaneous renal cryoablation (PRC) experience between January 2003 and April 2007. Patients with at least 12 months of follow-up were included in the analysis. Follow-up consisted of imaging and laboratory studies at regular intervals. Persistent mass enhancement or interval tumor growth was considered a treatment failure. Results: Sixty-six patients (44% women=56% men; 42% African-American=58% Caucasian=other; mean body mass index, 29.7) with 72 tumors underwent either LRC (n ¼ 52) or PRC (n ¼ 20) with a mean follow-up of 30 months (median 25.1 mos; range 13-63 mos). Average patient age was 66.5 years (range 34-82 yrs). Mean tumor size was 2.33 cm (range 1-4.6 cm). Comorbid conditions were prevalent: 76% hypertension, 36% hyperlipidemia, 24% chronic kidney disease, 29% diabetes mellitus, 36% tobacco use, and 32% heart disease. Results of pretreatment biopsy were 62% renal-cell carcinoma and 38% benign or nondiagnostic. Overall cancer-specific and cancer-free survival were 100% and 97%, respectively. There were two treatment failures (3.8%) in the LRC group and five primary failures in the PRC group (25%) (P ¼ 0.015), four of which were salvaged with repeated PRC with no evidence of recurrence at 6 to 36 months of follow-up. There has been no significant local or metastatic progression. Conclusions: LRC and PRC achieved good oncologic control with minimal morbidity at a mean follow-up of 30 months in a patient cohort characterized by numerous comorbid conditions. PRC had a significantly higher primary treatment failure rate than LRC, but re-treatment offered salvage oncologic control with no significant complications.
Introduction

B
ecause of the widespread use of abdominal imaging, the detection of asymptomatic small renal masses is increasingly prevalent. In the United States, there were 31,000 new kidney cancer cases expected in 2003 and more than 51,000 new cases expected in 2007. 1, 2 Although extirpative nephron-sparing surgery remains the gold standard for most small renal masses, increasing evidence supports the safety and efficacy of cryoablation. With abundant evidence for short-term oncologic control and a favorable morbidity profile, [3] [4] [5] longer-term oncologic outcomes are needed to determine the proper role of cryoablation in the urologist's armamentarium. Toward this end, we report our singlecenter experience with percutaneous and laparoscopic cryoablation of small renal masses with a mean follow-up of 30 months.
Patients and Methods
After obtaining Institutional Review Board approval, we retrospectively reviewed the records of patients with at least 12 months of follow-up after percutaneous renal cryoablation (PRC) or laparoscopic renal cryoablation (LRC) at our institution between January 2003 and April 2007. During the study period, 69 patients were treated. After exclusions for incomplete records or follow-up of fewer than 12 months, 66 patients (72 tumors) were included in the analysis.
Patient demographic information (age, race, sex, medical comorbidities), pertinent laboratory values, operative= procedural details, imaging results, pathology, and treatmentrelated complications were recorded and compared using the Student t test and the Fisher exact test. LRC was performed by three urologists (RG, RL, and MF [39 of 52 lesions treated]), and PRC was performed by two interventional radiologists (HV, SS).
Initially, cryoablation was offered to patients with a small renal mass who were felt to be at high risk for significant complications from extirpative surgery. With experience, application of cryoablation was extended to any patient with a small renal mass and no evidence of metastatic disease. In general, LRC was used for anterior tumors and PRC was preferred for posterior renal lesions.
LRC
A three-port configuration was used, with the camera port at the umbilicus and secondary ports at the subxiphoid location and at the level of the umbilicus in the midclavicular line. When necessary, a fourth port was placed inferior to the right costal margin to provide liver retraction for right-sided cryoablation. After reflecting the colon and exposing the Gerota fascia, intraoperative ultrasonography was used to localize the tumor.
An 18-gauge biopsy needle was passed percutaneously via a 14-gauge angiocatheter sheath to avoid tract seeding. Biopsy was performed under ultrasonographic guidance for all solid lesions. Biopsy was deferred in six cases of cystic-appearing lesions because of concern for potential seeding.
We used an argon-based cryoablation system (Endocare, Irvine, CA) with 1.7, 2.4, 3.8, 5.0, and 8.0 mm probes. Choice of size and number of cryoprobe(s) was based on tumor size and shape. Probe positioning was performed with ultrasonographic guidance, and double freeze-thaw cycles (10-minute freeze followed by passive thaw) followed with ultrasonographic monitoring (Doppler imaging was used before treatment, but we did not routinely repeat Doppler imaging after freeze-thaw cycles). To encompass the tumor within the À408C isotherm, visible ice was extended 1 cm beyond the tumor margins.
After tumor ablation, hemostatic agents such as Tiseel or Floseal (Baxter, Glendale, CA) were applied to the cryoablation site. After confirming hemostasis at reduced pneumoperitoneal pressures, the Gerota fascia was repositioned over the ablation site, and all port sites were evacuated, irrigated, and closed.
PRC
All PRC procedures were performed by an interventional radiologist using CT guidance with rapid reconstruction capability (SmartStep, GE Medical). Most procedures were performed with intravenous sedation, a method with established feasibility. 4 Discretionary general or monitored anesthesia was used if significant difficulty with patient cooperation was anticipated, or severe comorbid illness necessitated more controlled monitoring.
All procedures were performed using Perc 17 or Perc 24 cryoprobes (Endocare, Irvine, Ca). The treatment goal was complete incorporation of the target mass with a 1-cm margin by visible ice. After coaxial core biopsies, cryoprobes were placed either perpendicular or parallel to the long axis of the mass, depending on access site and lesion geometry. The standard treatment protocol consisted of a 10-minute freeze cycle, followed by an 8-minute thaw cycle and additional 10-minute freeze. Ice ball progress was monitored with intermittent CT scans. With probes still in place, final images were obtained after intravenous contrast administration and a 90-second imaging delay. This allowed for assessment of cryoablation effect and potential vascular complications.
Follow-up
Follow-up after renal tumor cryoablation at our center includes serial contrast-enhanced CT imaging at 1, 3, 6, 12, 18, and 24 months, with annual imaging thereafter. Follow-up imaging was obtained with 8, 16, or 64-slice multidetector CT scanners with collimation ranging from 0.625 to 1.25 mm (GE Healthcare, Milwaukee, WI). High-resolution surveillance imaging allows for early detection of enhancing foci less than 1 mm. If there is an increase in tumor size or persistent enhancement, the procedure is deemed a failure, and the patient is offered re-treatment with either cryoablation or extirpative surgery. At each scheduled follow-up visit, a physical examination is performed, and appropriate laboratory studies are obtained.
Results
Sixty-six patients (72 lesions) with at least a 12-month follow-up were included in the analysis (44% women=56% men; 42% African-American=58% Caucasian=other). Patient demographic information is shown in Table 1 . Mean patient age was 66.5 years (range 34-82 yrs). Mean body mass index was 29.7 (range 19.6-39.9). Medical comorbidities were highly prevalent, with incidences of 76% hypertension, 24% chronic kidney disease, 36% hyperlipidemia, 29% diabetes mellitus, 36% tobacco use, and 32% heart disease (coronary artery disease or congestive heart failure). Average tumor size was 2.33 cm (range 1-4.6 cm).
Forty-six patients (52 lesions) were treated with LRC and 20 patients (20 lesions) were treated with PRC. In general, anterior tumors were managed with LRC while posterior tumors were managed with PRC. There were no statistically significant differences between the two groups with respect to age, race, sex distribution, or comorbid conditions. Results of pretreatment biopsy were 62% renal-cell carcinoma (RCC) (32 clear-cell, 7 papillary, 2 chromophobe) and 38% benign or nondiagnostic (Table 1) .
At a mean follow-up of 30 months (median 25 mos; range 13-63 mos), overall cancer-specific and cancer-free survival were 100% and 97%, respectively. There were two (3.8%) primary treatment failures in the LRC cohort and five (25%) primary local failures in the PRC cohort (P ¼ 0.015). Patient, tumor, and treatment characteristics of the primary failures are shown in Table 2 .
The first LRC failure was a case of a 1.5 cm mass that showed a 3-mm enhancing focus within the cryolesion at 3-month follow-up imaging. Re-treatment was recommended, but the patient declined. Over the ensuing 12 months of follow-up, there were no demonstrable changes on serial imaging. The second LRC failure was a case of a 2-cm RCC 908 MALCOLM ET AL.
that showed stepwise size reduction without enhancement over the first 18 months of follow-up. At the 2-year follow-up, however, there was a small focus of enhancement adjacent to the cryolesion, and CT-guided biopsy confirmed the presence of RCC. The patient was subsequently treated with open partial nephrectomy and has had negative imaging over the ensuing 18 months of follow-up. Four of five patients with primary treatment failure after PRC had salvage treatment with repeated PRC, demonstrating no recurrent enhancement or tumor growth during 6 to 36 months of secondary follow-up. The fifth patient who underwent secondary PRC had a small focus of enhancement within the cryolesion at 3-month follow-up imaging. The patient declined further intervention, and the radiographic appearance has been stable over a 12-month follow-up. There have been no cases of significant local progression or progression to metastatic disease.
Operative and perioperative complications were infrequent. Mean change in hemoglobin level was À0.96 g=dL (LRC À1.19, PRC À0.33, P ¼ 0.02) with a range of À2.6 g=dL to 0 g=dL. Blood transfusions were administered in two cases after LRC. The first was a case of multifocal tumors measuring 2.4 and 1.5 cm, each managed with a 3.8-mm cryoprobe. The second was a case of a single 3.8-cm right upper pole tumor managed with a 3.8-mm cryoprobe. In both cases, hemodynamic stability was achieved after a 2-unit blood transfusion.
Mean hospital stay was 2 days (LRC 3, PRC 1, P ¼ 0.004) with a range of 1 to 9 days. One patient had a 9-day hospital stay (after LRC) for prolonged ileus vs partial small bowel obstruction that resolved with bowel rest. A second patient needed a 5-day hospital stay (after LRC) for prolonged ileus. There were no thromboembolic events, urinary tract infections (UTIs), urine leaks, wound infections, or perioperative cardiac events. During the study period, a single death was noted in a patient who had nonpathologic femur fractures and died from pulmonary complications after a prolonged hospital course.
Discussion
We present a 2.5-year oncologic follow-up on a series of 66 patients who were treated with percutaneous or laparoscopic cryoablation of small renal masses. Aggregate oncologic outcomes were favorable in this cohort, with an overall cancer-specific and cancer-free survival of 100% and 97% at a mean follow-up of 30 months. Cancer-free survival after a 6 reported a series of 120 tumors managed percutaneously with MRI guidance. At a mean follow-up of 35 months, 72 (60%) tumors were successfully ablated with a single cryotreatment, while an additional 33 (27.5%) tumors needed at least one re-treatment to achieve successful tumor ablation. In 48 patients followed for a median of 64 months, Davol and associates 7 reported an 87.5% cancer-free survival rate after a single cryotreatment, with 97.5% cancer-free survival after repeated treatments.
A recent meta-analysis that compared percutaneous and surgical (laparoscopic=open) renal cryoablation found a significantly greater primary treatment effectiveness with surgical cryoablation (cancer-free survival 94% vs 87%, P < 0.05), but a statistically equivalent treatment effect when re-treatment outcomes were considered (cancer-free survival 95% vs 92%, P > 0.05). 8 Our experience with renal cryoablation is consistent with the growing body of literature indicating that successful tumor management necessitates vigilant follow-up and not infrequent re-treatment, particularly in the case of PRC. It is important to counsel patients accordingly.
Notwithstanding the fact that our cohort was characterized by a high prevalence of medical comorbidities, cryoablation procedures were well tolerated, with few complications. Two patients received blood transfusions, and two patients from the laparoscopic cohort needed hospital stays of 5 and 9 because of prolonged ileus. There were no cases of urine leak, UTI, wound infection, thromboembolic event, or other significant perioperative morbidity. Mean length of hospital stay was significantly shorter in the percutaneously treated cohort (1 vs 3 days, P ¼ 0.004).
The tolerability and favorable morbidity profile of renal cryoablation has been well established, particularly in comparison with extirpative treatment options. 9, 10 Most published series have reported low rates of major complications, on the order of 1% to 6%. [9] [10] [11] These data enhance the appeal of renal cryoablation for the management of small renal masses, which are often benign or may be unlikely to progress. 12 What remains to be seen is how cryoablated small renal masses will behave during long-term follow-up. Twenty-two patients in our series have follow-up longer than 3 years, and there have been no cases of local recurrence beyond 2 years of follow-up. One case of particular concern in our series, however, is the patient in whom local recurrence of RCC developed at 2 years after LRC, despite incremental size reduction of the cryolesion on early follow-up imaging. While such a delayed recurrence appears to be an uncommon event, longterm continuous follow-up is mandatory, because favorable early follow-up imaging does not exclude the possibility of local recurrence.
A small number of substantial series with long-term followup have been published. Hegarty and colleagues 13 reported 5-year outcomes of 60 patients who were treated with laparoscopic cryoablation. Overall and cancer-specific survival rates were 82% and 100%, respectively, with local tumor recurrence developing in three (6.7%) patients. Similar 5-year outcomes were reported by Davol and coworkers, 7 with 97% cancer-free survival in 48 patients who were treated with open crenal cryoablation or LRC.
As numerous series mature toward 5-and 10-year outcomes, it will be important to continue to reevaluate the oncologic efficacy of renal cryoablation, which currently shows considerable promise. In our current clinical practice, we maintain a preference for extirpative management of small renal masses, because it is time-tested, yields superior pathologic information, and simplifies follow-up to a significant degree. Given the tolerability and efficacy of cryoablation, however, we currently offer it to all patients with small renal masses as a first-line alternative to open or laparoscopic partial nephrectomy. We are finding that patients, when presented with the available treatment alternatives and risk=benefit profiles of each, choose cryoablation with increasing regularity.
In our series, factors that appeared most prominently to impact treatment outcome were mode of treatment delivery and tumor location. The first LRC failure in our series occurred in a perihilar right interpolar tumor. The ''heat sink effect'' of the hilar vasculature is well established and may prevent the cryoprobe from achieving lethal temperatures in the desired treatment area. 6 Local failure was also significantly more common in upper pole tumors that were managed percutaneously. This appears to have been a function of the learning curve. Three of the five percutaneous failures were among the first four patients treated with PRC. All tumors were located in the upper pole, and there was particular concern for freezing in close proximity to the costophrenic sulcus and lower lung. With experience and increased comfort level with PRC, upper-pole tumor ablation has appeared less problematic. It may be prudent for urologists and interventional radiologists to avoid extreme upper-pole tumors early in their PRC experience.
Weaknesses of this study include its retrospective design, with its inherent limitations. In addition, as with all reports on renal cryoablation, the evaluation of efficacy is based on core needle biopsy and radiographic imaging, both of which are known to have limitations. Follow-up of cryoablated lesions is not standardized, but it is likely that routine post-treatment biopsies should be included in the follow-up algorithm, because recent reports have demonstrated that post-treatment radiographic imaging may not correlate with histopathology.
14 Although we now recommend that patients undergo routine rebiopsy of cryolesions at 6-and 18-month followup, the series reported here predates this management strategy.
Finally, the 2.5 year oncologic outcomes we report should be measured against the natural history of small renal masses. It is known that many small renal masses behave in an indolent fashion, often progressing slowly with little propensity for metastasis. In a meta-analysis of more than 6000 small renal masses, there was no significant difference in rates of metastasis between masses managed with excision, ablation, or observation. 12 In this context, we recognize that absence of local progression and metastases in our series does not necessarily make a strong case for cryoablation of small renal masses. Longer-term follow-up is requisite. These limitations notwithstanding, this analysis is strengthened by a robust period of follow-up on a sizeable cohort of patients from a single institution.
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Conclusions
Laparoscopic and percutaneous cryoablation of small renal lesions were well-tolerated and offered good oncologic efficacy during intermediate-term follow-up. LRC was associated with significantly lower primary failure rates than PRC but is more invasive and was associated with a longer hospital stay. Both LRC and PRC resulted in more than 95% cancerfree survival at 30-month follow-up. Patients should be counseled that secondary cryotreatment might be necessary to achieve this outcome.
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